furthermore if OSX is a 60 million market cap with 3 million in cash as a biotech which is trialing in Singapore on a biotech with a small target market and NYR is a 16 million market cap with 10 million in cash in the same position in the life cycle of a biotech company which the target market is 50 billion dollar market with stroke and traumatic brain injury yeh it’s severely undervalued and give me that easy accumulation
Always about fundamentals doesn’t matter about the day traders it matters about what’s already proven and the news flow hitting short term further developing this multi billion dollar drug
Ann: Investor Presentation - April 2024, page-9
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.005(4.55%) |
Mkt cap ! $24.10M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 12.0¢ | 11.0¢ | $164.0K | 1.456M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 742920 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 254495 | 3 |
View Market Depth
| Last trade - 16.10pm 04/11/2024 (20 minute delay) ? |
| NYR (ASX) Chart |